Figure 1.

Meta-analysis of PROWESS and ADDRESS patients with APACHE II score (AP) ≥ 25 using output from standard meta-analysis software (Review Manager, Version 4.2). The results from the following three methods are presented: method 1, a fixed effect model demonstrating a risk ratio using weights for ADDRESS and PROWESS of 18.17% and 81.83%, respectively; method 2, a random effect model demonstrating a risk ratio using weights for ADDRESS and PROWESS of 45.35% and 54.65%, respectively; and method 3, a fixed effect model demonstrating a Peto odds ratio using weights for ADDRESS and PROWESS of 24.97% and 75.03%, respectively. The risk ratios (RR) and odds ratio (OR) are plotted on a natural logarithm scale. n/N equals number of deaths at 28 days/number of patients for each particular group. Each method has a Chi-square test for heterogeneity, degrees of freedom (df) that is 1 less than the number of studies and a p value < 0.05, indicating heterogeneity. A point estimate to the left of the line of identity (1) favors treatment with Drotrecogin alfa (activated) and an estimate to the right favors placebo. A 95% confidence interval (CI) is included for each point estimate.